Healthcare

BCAL Diagnostics Limited (ASX:BDX) has captured the attention of Australian stock market participants as the Sydney-based biotech stock pushes ahead with the commercial roll-out and validation of its breast cancer blood-screening technology. Following a run of ASX announcements covering expanded national access pathways, a …

Cambium Bio Limited (ASX:CMB) has drawn renewed attention on the Australian stock market as its share price eases and traders weigh what might come next. The clinical-stage regenerative medicine company, formed through the 2024 merger of Regeneus and US-based Cambium Medical Technologies, is advancing …

Amplia Therapeutics (ASX:ATX) has emerged as one of the more closely watched names among Australian biotech stocks in 2026. The Melbourne-based clinical-stage drug developer has reported a steady stream of clinical milestones for its lead candidate, narmafotinib, an experimental treatment for advanced pancreatic cancer. …

For a small-cap biotech, securing alignment with the FDA — the world's most influential drug regulator — is a meaningful form of progress. It signals that the company and the regulator share an understanding of important aspects of the development pathway, which can reduce …

Key TakeawaysActinogen Medical Limited (ASX:ACW) is a Sydney-based clinical-stage biotech stock developing Xanamem, a cortisol-targeting therapy for neurological conditions including Alzheimer’s disease.Investor interest in the small-cap stock has been driven by 2026 milestones, including an interim recommendation to continue its pivotal trial, the start …

BCAL Diagnostics (ASX:BDX) is fast becoming one of the most closely followed names in Australian medical diagnostics, and in 2026 the small-cap biotech is back in the spotlight after advancing a novel blood test aimed at breast cancer. For retail investors scanning the ASX …

Clever Culture Systems (ASX:CC5) has moved into the growth lane after securing an evaluation with biotech heavyweight CSL for its APAS microbiology platform — a development that has put this ASX-listed medtech firmly on the radar of Australian investors in 2026. For retail investors …